All opioid medicines to contain clear warnings about addiction, health secretary announces All opioid medicines will need to carry prominent warnings about the risk of addiction, health and social care secretary, Matt Hancock, has announced.…
Bulk shipment of medical cannabis delivered to UK What is thought to be the first bulk shipment of medical cannabis brought into the UK was delivered on 14 February 2019.…
MHRA expert working group launches review of opioid use An expert working group of the UK’s Commission on Human Medicines, a committee within the Medicines and Healthcare products Regulatory Agency, has launched a review looking into the risks and benefits of opioid medicines.…
MHRA issues further recall for irbesartan The Medicines and Healthcare products Regulatory Agency has recalled more irbesartan-containing blood pressure and heart medication from UK pharmacies as it continues to investigate possible contamination of sartan products.…
FMD compliance to be part of pharmacy inspections Existing pharmacy inspection processes will be used to monitor pharmacies’ compliance with the Falsified Medicines Directive, the General Pharmaceutical Council has announced.…
MHRA confirms it will consider UK version of Falsified Medicines Directive With less than a month until the Falsified Medicines Directive is implemented on 9 February 2019, the Medicines and Healthcare products Regulatory Agency has confirmed that if there is a no-deal Brexit it will consider a UK-only version of the EU law.…
Government publishes additional no-deal Brexit medicines regulation guidance More information on how medicines, medical devices and clinical trials would be regulated following a no-deal Brexit has been issued by the Department of Health and Social Care.…
Emollient packaging should include fire risk warning, says MHRA People who use emollient creams to treat dry and itchy skin conditions should be warned about the potential fire hazard, the Medicines and Healthcare products Regulatory Agency has said.…
FMD regulations won’t apply after ‘no-deal’ Brexit, says MHRA Pharmacies will have no legal obligation to implement the Falsified Medicines Directive in the event of a ‘no-deal’ Brexit, the Medicines and Healthcare products Regulatory Agency has confirmed.…
MHRA consults on medicine regulation to plan for possible no-deal Brexit The UK’s medicines safety watchdog has asked for views on how it could behave as a stand-alone regulatory body in the event of a no-deal Brexit.…